Patient-Reported Outcomes From a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
posted on 2021-03-05, 17:03authored byAnca D. Askanase, George J. Wan, Mary P. Panaccio, Enxu Zhao, Julie Zhu, Roman Bilyk, Richard A. Furie
Article full
text
The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).